Floatz logo

FILGRASTIM

Recurrent Adult Diffuse Mixed Cell Lymphoma

Fred Hutchinson Cancer Centerprotein_peptidePhase 3Dormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Recurrent Adult Diffuse Mixed Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Fludarabine
Case Comprehensive Cancer Center
Phase 2BBB
CYCLOSPORIN A
National Cancer Institute (NCI)
Phase 2BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Mayo Clinic
Phase 2BBB
Monomethyl Fumarate
University of Medicine and Dentistry of New Jersey
Phase 2BBB
ETOPOSIDE
Fred Hutchinson Cancer Center
Phase 3BBB

View all 50 →

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →